Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Ra Capital Management, L.P.
Form 13F · Q2 2026

Ra Capital Management, L.P.

CIK 1346824Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$11.5B
Reported book value
85
Positions
12
Quarters on record
Top 50
Positions

Ra Capital Management, L.P. — holdings

Top 50 positions of 85, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1ASND Ascendis Pharma A/S10.3M—$2.7B23.8%
2PBLS Parabilis Medicines Inc28.9M—$792M6.9%
3RYTM Rhythm Pharmaceuticals Inc6.7M+0.0%$740M6.4%
4PCVX Vaxcyte Inc11.5M+0.0%$667M5.8%
5SION Sionna Therapeutics Inc9.9M+0.0%$436M3.8%
6TYRA Tyra Biosciences Inc12.2M+0.0%$390M3.4%
7EWTX Edgewise Therapeutics Inc8.4M−19.5%$341M3.0%
8NAMS Newamsterdam Pharma Company9.6M+0.0%$324M2.8%
9COAG Hemab Therapeutics Hldgs Inc7.8M—$287M2.5%
10SEPN Septerna Inc7.0M+0.0%$234M2.0%
11BCAX Bicara Therapeutics Inc7.3M+0.0%$215M1.9%
12MLYS Mineralys Therapeutics Inc7.7M+0.0%$208M1.8%
13GHRS Gh Research Plc7.6M−0.5%$205M1.8%
14IRON Disc Medicine Inc2.5M+0.0%$179M1.6%
15SGP Spyglass Pharma Inc8.0M+0.0%$179M1.6%
16ARTV Artiva Biotherapeutics Inc18.0M+82.2%$174M1.5%
17JANX Janux Therapeutics Inc11.2M+0.0%$172M1.5%
18TSHA Taysha Gene Therapies Inc23.6M+0.0%$160M1.4%
19BCRX Biocryst Pharmaceuticals Inc15.8M+0.0%$158M1.4%
20WVE Wave Life Sciences Ltd27.0M+0.0%$157M1.4%
21NUVALENT INC Nuvalent Inc1.2M−50.8%$154M1.3%
22ABIVAX SA Abivax Sa1.1M—$151M1.3%
23ORKA Oruka Therapeutics Inc1.6M—$148M1.3%
24CLYM Climb Bio Inc11.3M+0.0%$147M1.3%
25SLDB Solid Biosciences Inc12.0M+28.9%$120M1.0%
26ZLAB Zai Lab Ltd5.7M+0.6%$109M0.9%
27SPRY Ars Pharmaceuticals Inc10.9M+0.0%$87M0.8%
28XNCR Xencor Inc5.3M+7.7%$85M0.7%
29JBIO Jade Biosciences Inc3.7M+0.0%$82M0.7%
30NTLA Intellia Therapeutics Inc4.5M—$77M0.7%
31LBRX Lb Pharmaceuticals Inc2.2M+0.0%$72M0.6%
32DFTX Definium Therapeutics Inc1.5M—$71M0.6%
33ACRS Aclaris Therapeutics Inc12.7M+87.0%$67M0.6%
34FDMT 4D Molecular Therapeutics In5.0M+0.0%$67M0.6%
35SANA Sana Biotechnology Inc18.8M—$65M0.6%
36DMRA Damora Therapeutics Inc2.4M+0.0%$62M0.5%
37MNPR Monopar Therapeutics Inc667,207+0.0%$62M0.5%
38ABOS Acumen Pharmaceuticals Inc21.0M+0.0%$56M0.5%
39GERN Geron Corp42.8M−32.9%$55M0.5%
40RZLT Rezolute Inc9.4M+2.9%$49M0.4%
41EVMN Evommune Inc3.5M+0.0%$46M0.4%
42VOR Vor Biopharma Inc2.4M−55.6%$44M0.4%
43IPSC Century Therapeutics Inc17.8M+0.0%$43M0.4%
44AKTS Aktis Oncology Inc1.3M−12.6%$42M0.4%
45BIOA Bioage Labs Inc1.7M+1.3%$41M0.4%
46CCCC C4 Therapeutics Inc8.0M+0.0%$37M0.3%
47MIRM Mirum Pharmaceuticals Inc318,554+0.0%$37M0.3%
48CAPR Capricor Therapeutics Inc1.5M+0.0%$36M0.3%
49PEPG Pepgen Inc20.1M+0.0%$36M0.3%
50PRLD Prelude Therapeutics Inc6.5M—$35M0.3%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.